Cardiff Oncology Inc (CRDF)
3.38
0.00 (0.00%)
USD |
NASDAQ |
May 10, 16:00
3.38
0.00 (0.00%)
After-Hours: 20:00
Cardiff Oncology Cash from Financing (TTM): 0.107M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 0.107M |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.075M |
March 31, 2023 | 0.075M |
December 31, 2022 | 0.075M |
September 30, 2022 | 15.04M |
June 30, 2022 | 14.96M |
March 31, 2022 | 34.19M |
December 31, 2021 | 35.45M |
September 30, 2021 | 120.24M |
June 30, 2021 | 132.58M |
March 31, 2021 | 136.12M |
December 31, 2020 | 137.31M |
September 30, 2020 | 42.00M |
June 30, 2020 | 31.16M |
March 31, 2020 | 11.29M |
December 31, 2019 | 12.08M |
September 30, 2019 | 7.637M |
June 30, 2019 | 6.147M |
March 31, 2019 | 18.35M |
December 31, 2018 | 16.40M |
September 30, 2018 | 20.47M |
June 30, 2018 | 26.84M |
March 31, 2018 | -4.929M |
Date | Value |
---|---|
December 31, 2017 | -6.378M |
September 30, 2017 | -10.51M |
June 30, 2017 | -13.22M |
March 31, 2017 | 2.381M |
December 31, 2016 | 2.301M |
September 30, 2016 | 3.491M |
June 30, 2016 | 38.39M |
March 31, 2016 | 42.63M |
December 31, 2015 | 64.55M |
September 30, 2015 | 63.48M |
June 30, 2015 | 24.93M |
March 31, 2015 | 36.21M |
December 31, 2014 | 14.48M |
September 30, 2014 | 14.39M |
June 30, 2014 | 36.20M |
March 31, 2014 | 22.87M |
December 31, 2013 | 22.98M |
September 30, 2013 | 27.39M |
June 30, 2013 | 5.585M |
March 31, 2013 | 14.50M |
December 31, 2012 | 15.32M |
September 30, 2012 | 12.01M |
June 30, 2012 | 12.55M |
March 31, 2012 | 2.863M |
December 31, 2011 | 2.574M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
Sep 2023
137.31M
Maximum
Dec 2020
36.83M
Average
13.52M
Median
Cash from Financing (TTM) Benchmarks
BioVie Inc | 15.36M |
Perspective Therapeutics Inc | 0.785M |
Biolase Inc | 17.43M |
Tenon Medical Inc | 6.302M |
Adial Pharmaceuticals Inc | 4.132M |